Showing results (601-610 of 622) with videos related to
Sort By:
Pageof 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE TrialFedro A Peccatori, Samuel M Niman, Ann H Partridge, et al.The Science of the Total Environment|November 8, 2023
Evaluating the extent and impact of the extreme Storm Gloria on Posidonia oceanica seagrass meadowsCandela Marco-Méndez, Núria Marbà, Ángel Amores, et al.Clinical and Experimental Rheumatology|August 3, 2023
Nailfold videocapillaroscopy patterns in systemic sclerosis: implications for cutaneous subsets, disease features and prognostic value for survivalCarles Tolosa-Vilella, Maria Del Mar Rodero-Roldán, Alfredo Guillen-Del-Castillo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2026
Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) TrialOlivia Pagani, Samuel M Niman, Monica Ruggeri, et al.Frontiers in Oncology|March 12, 2026
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern SpainAlejandro Falcón-González, Elisenda Llabrés-Valenti, Fernando Henao-Carrasco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)Ana Lluch, Carlos H Barrios, Laura Torrecillas, et al.Journal of Medical Virology|January 14, 2023
Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trialAlejandro Morales-Ortega, Ana Isabel Farfán-Sedano, Juan Víctor San Martín-López, et al.Autoimmunity Reviews|March 21, 2020
Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validationManuel Rubio-Rivas, Xavier Corbella, Alfredo Guillén-Del-Castillo, et al.The Lancet. Oncology|January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L Mayer, Amylou C Dueck, Miguel Martin, et al.Autoimmunity Reviews|August 5, 2022
Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)Cristina Carbonell, Miguel Marcos, Alfredo Guillén-Del-Castillo, et al.Pageof 63